Studying patient experiences with treatment for advanced gynecologic cancers
Asks people with advanced cervical or endometrial cancer about treatment choices and follow-up needs.
Plain-language title generated from the registry record
Registry title: Patient Journey in Advanced Gynecologic Cancers
Key facts
- Where
- Chongqing, Guangzhou, Hefei, and Wuhan, ChinaSee the 4 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with newly diagnosed stage III or IV cervical or endometrial cancer who finished their first treatment and whose disease is stable. It is a survey and interview study.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Newly diagnosed stage III or IV cervical cancer or endometrial cancer; the doctor says the disease is stable
- Earlier treatment
- Must have finished first treatment between Dec. 2022 and Dec. 2024, including at least chemotherapy, radiotherapy or both, within 6 months after diagnosis. Must not have had anti-PD-1, anti-PD-L1 or anti-PD-L2 therapy.
Main reasons for not taking part
- Earlier treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs, or drugs aimed at another T-cell receptor
- Took part or is taking part in a clinical trial
- Got another line of therapy after the first treatment
- Not fluent in the local language
- Hearing difficulties that make a conversation hard
Read by machine on 9 November 2026.
Where in China
- Dongling ZouChongqing, ChinaNo longer taking part
- Shuzhong YaoGuangzhou, ChinaNo longer taking part
- Ying ZhouHefei, ChinaNo longer taking part
- Gang ChenWuhan, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tongji Hospital
- Trial code
- NCT07015593
- Record updated
- 11 June 2025
- Original description
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.Read full original descriptionShow less
Patient Journey in Conventional Therapy for Primarily Treated Advanced Gynecologic Cancers in China
This is a mixed-methods survey study including a 2-phased sequential-explanatory design. This study is to understand the patient journey in conventional therapy for newly diagnosed stage III or IV CC or EC in China, including ①patients' treatment decision making factors and treatment experiences and ② patients' unmet needs during post-treatment surveillance.
Inclusion: Age 18 or older; Newly diagnosed stage III or IV CC or EC; Completed their initial conventional therapies which must include at least chemotherapy, radiotherapy or a combination between Dec. 2022 to Dec. 2024 and the therapies were within 6 months after diagnosis; Told by their physician that their disease is stable; Patients must have informed consent form (ICF) signed for the study.
Exclusion: Previously treated with targeted biologic therapy anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor; Previously participated in or participating in a clinical trial; Patients who received another line of therapy after initial therapy; Unable or unwilling to provide informed consent; Not fluent in local language; Indicates or exhibits hearing difficulties, which would make a conversation challenging.